SCHEDULE: Galloway Capital Discloses 8.42% Stake in WW International

Galloway Capital Partners announces beneficial ownership of 8.42% of WW International's common stock, citing undervaluation and strategic opportunities.

Summary

• Galloway Capital Partners, LLC, along with its affiliates, has disclosed beneficial ownership of approximately 8.42% of WW International, Inc.'s outstanding common stock.
• This stake includes 378,700 shares of common stock and 463,000 shares underlying call options exercisable within 60 days.
• The acquisition of shares occurred through open market purchases between March and May 2026, with an average price of approximately $12.26 per share.
• The call options were purchased for an aggregate price of $569,490.
• Galloway Capital Partners views WW International as materially undervalued, considering its brand recognition, strategic positioning in weight management, metabolic health, and longevity sectors, and its established clinical platform.
• The firm believes the company's equity valuation has declined dramatically despite a significantly improved capital structure post-restructuring, which reduced debt from approximately $1.4 billion to $460 million and retained over $220 million in cash.
• Galloway Capital Partners intends to review its investment continuously and may engage with the Board and management regarding the company's performance, operations, management, governance, capital allocation, and strategy.
• A letter was sent to WW International's management on May 13, 2026, outlining these views and intentions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating a significant investor believes the company is undervalued and possesses strong strategic assets, with potential for value creation through engagement.

Positives

• WW International possesses a strong, recognized, and trusted brand in consumer wellness.
• The company is positioned within the growing weight management, metabolic health, and longevity sectors.
• A recent restructuring significantly improved the capital structure, reducing debt from approximately $1.4 billion to $460 million.
• The company retained over $220 million in cash on its balance sheet post-restructuring.
• The clinical business is growing in excess of 50% annually with attractive margins.
• The company maintains access to a proprietary database and customer acquisition engine with approximately 2.7 million current members and millions of former members.
• This member ecosystem offers significant strategic optionality across adjacent health verticals.

Negatives

• The company was reportedly late in entering the GLP-1 ecosystem.
• Despite a substantially improved capital structure, the equity valuation has declined dramatically since the restructuring.
• The stock price has fallen from approximately $46 per share post-restructuring to a valuation of less than $100 million.
• WW International is trading at approximately 3.7x EBITDA, a substantial discount to comparable companies.

Risks

• The company's current valuation may not reflect the strength of its brand, the strategic value of its member ecosystem, the growth trajectory of its clinical platform, or future opportunities.
• Future actions by Galloway Capital Partners regarding its investment are dependent on various factors including market conditions, company performance, and strategic alternatives.

Future Outlook

Galloway Capital Partners intends to review its investment in WW International on a continuing basis and may acquire additional securities, retain or sell existing shares, or engage with the Board and management on various strategic and operational matters. The firm believes the company's current valuation fails to reflect its potential and that it is worth a multiple of its current trading value.

Management Comments

• "We believe the Company is materially undervalued relative to both its intrinsic value and its strategic positioning within one of the fastest-growing sectors globally: weight management, metabolic health, and longevity."
• "WW possesses one of the most recognized and trusted brands in consumer wellness."
• "While the Company was admittedly late entering the GLP-1 ecosystem, it is now firmly positioned within that market and has established a strong clinical platform."
• "Despite this substantially improved capital structure, the Company's equity valuation has declined dramatically."
• "At current levels, WW is trading at approximately 3.7x EBITDA, a substantial discount to comparable companies within the broader digital health and wellness ecosystem."
• "We further believe that the Company's clinical business alone, which is currently growing in excess of 50% annually and generating attractive margins may be worth multiples of the Company's entire current enterprise valuation."
• "This represents an extraordinarily valuable proprietary database and customer acquisition engine in an era increasingly focused on wellness, preventive healthcare, longevity, and personalized medicine."
• "In our view, WW's current valuation fails to reflect the strength of its brand, the strategic value of its member ecosystem, the growth trajectory of its clinical platform, or the significant opportunities ahead."
• "We believe the Company is worth a multiple of its current trading value."

Industry Context

StockSavvy.ai notes that Galloway Capital's engagement with WW International highlights a trend of activist investors scrutinizing companies in the health and wellness sector, particularly those with strong brands that may be undervalued due to recent restructuring or market shifts. The comparison to Hims & Hers suggests a belief that WW International's clinical and data assets could command higher multiples if effectively leveraged.

Comparison to Industry Standards

• Hims & Hers Health, Inc. (NYSE: HIMS) currently trades at EBITDA multiples in the mid-20x range, significantly higher than WW International's 3.7x EBITDA multiple.
• The digital health and wellness ecosystem generally sees higher EBITDA multiples compared to WW International's current valuation.

Management Changes

Stakeholder Impact

• Shareholders may benefit from potential value creation initiatives proposed by Galloway Capital Partners.
• Management and the Board of Directors will likely engage with Galloway Capital Partners regarding strategic direction and governance.
• Employees may experience changes depending on the strategic direction pursued by the company following investor engagement.

Next Steps

• Galloway Capital Partners intends to review its investment in WW International on a continuing basis.
• The firm may acquire additional securities, retain or sell existing shares.
• Galloway Capital Partners intends to engage with the Board and management regarding the company's performance, operations, management, governance, capital allocation, and strategy.

Key Dates

Recommendation

The filing indicates a significant investor believes WW International is undervalued and plans to engage with management. While this suggests potential upside, the outcome of this engagement is uncertain. A 'hold' recommendation is appropriate pending further developments or clearer strategic direction from the company or the activist investor.

Keywords

WW International, Galloway Capital Partners, Schedule 13D, Beneficial Ownership, Activist Investor, Weight Management, Metabolic Health, Longevity, Digital Health, Wellness, Call Options, Capital Structure, EBITDA